A LAG-3-Specific Agonist Antibody for the Treatment of T Cell-Induced Autoimmune Diseases.
Animals
Antibodies, Monoclonal, Humanized
/ pharmacology
Antigens, CD
/ drug effects
Autoimmune Diseases
/ immunology
Autoimmunity
/ drug effects
Cell Proliferation
/ drug effects
Humans
Hypersensitivity, Delayed
/ immunology
Immunosuppressive Agents
/ pharmacology
Lymphocyte Activation
/ drug effects
Macaca fascicularis
Male
T-Lymphocytes
/ drug effects
Lymphocyte Activation Gene 3 Protein
Journal
Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R
Informations de publication
Date de publication:
15 02 2020
15 02 2020
Historique:
received:
16
07
2019
accepted:
06
12
2019
pubmed:
8
1
2020
medline:
15
9
2020
entrez:
8
1
2020
Statut:
ppublish
Résumé
T cells chronically stimulated with the same peptide tend to express exhaustion markers such as PD-1 or LAG-3. Deficiencies in the PD-1 and LAG-3 pathways have been linked to the development of autoimmune diseases. IMP761 is a LAG-3-specific humanized agonist Ab with immunosuppressive properties both in vitro and in vivo in an Ag-specific delayed-type hypersensitivity (DTH) model in the cynomolgus macaque (
Identifiants
pubmed: 31907283
pii: jimmunol.1900823
doi: 10.4049/jimmunol.1900823
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antigens, CD
0
Immunosuppressive Agents
0
Lymphocyte Activation Gene 3 Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
810-818Informations de copyright
Copyright © 2020 by The American Association of Immunologists, Inc.